Aeluma (ALMU) 10-Q 12 Feb 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2023	Feb. 09, 2024
Document Information Line Items
Entity Registrant Name	AELUMA, INC.
Document Type	10-Q
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		12,178,424
Amendment Flag	false
Entity Central Index Key	0001828805
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-56218
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-2807351
Entity Address, Address Line One	27 Castilian Drive
Entity Address, City or Town	Goleta
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	93117
City Area Code	(805)
Local Phone Number	351-2707
Title of 12(b) Security	None
Entity Interactive Data Current	Yes

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,423,054	$ 5,071,690
Accounts receivable	192,992	189,239
Deferred compensation, current portion	27,925	53,034
Prepaids and other current assets	155,647	19,943
Total current assets	2,799,618	5,333,906
Property and equipment:
Equipment	1,373,946	1,209,656
Leasehold improvements	546,864	546,864
Accumulated depreciation	(430,728)	(300,445)
Property and equipment, net	1,490,082	1,456,075
Intangible assets	8,333	9,833
Right of use asset - facility	1,012,342	351,013
Deferred compensation, long term portion	6,171
Other assets	13,014	13,014
Total assets	5,329,560	7,163,841
Current liabilities:
Accounts payable	162,823	461,797
Accrued expenses and other current liabilities	163,900	133,092
Lease liability, current portion	124,145	162,210
Total current liabilities	450,868	757,099
Lease liability, long term portion	1,006,736	296,452
Total liabilities	1,457,604	1,053,551
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and none issued and outstanding at December 31, 2023 and June 30, 2023
Common stock, $0.0001 par value; 50,000,000 shares authorized at December 31, 2023 and June 30, 2023, and 12,167,930 and 12,817,500 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively	1,217	1,282
Additional paid-in capital	15,543,634	15,171,074
Accumulated deficit	(11,672,895)	(9,062,066)
Total stockholders’ equity	3,871,956	6,110,290
Total liabilities and stockholders’ equity	$ 5,329,560	$ 7,163,841

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Jun. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	12,167,930	12,817,500
Common stock, shares outstanding	12,167,930	12,817,500

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 262,992		$ 295,392
Operating expenses:
Cost of revenue	136,767		151,906
Research and development	651,099	767,784	1,485,968	1,604,260
General and administrative	603,925	387,110	1,269,028	1,117,321
Total expenses	1,391,791	1,154,894	2,906,902	2,721,581
Loss from operations	(1,128,799)	(1,154,894)	(2,611,510)	(2,721,581)
Other income:
Sub-lease income & other income		74,165		110,516
Interest income	279	180	681	475
Total other income	279	74,345	681	110,991
Loss before income tax expense	(1,128,520)	(1,080,549)	(2,610,829)	(2,610,590)
Income tax expense
Net loss	$ (1,128,520)	$ (1,080,549)	$ (2,610,829)	$ (2,610,590)
Loss per share - basic (in Dollars per share)	$ (0.09)	$ (0.1)	$ (0.21)	$ (0.24)
Weighted average common shares outstanding - basic (in Shares)	12,167,930	10,795,872	12,418,579	10,722,937

Consolidated Statements of Op_2

Consolidated Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Loss per share -diluted	$ (0.09)	$ (0.10)	$ (0.21)	$ (0.24)
Weighted average common shares outstanding - diluted	12,167,930	10,795,872	12,418,579	10,722,937

Consolidated Statement of Stock

Consolidated Statement of Stockholders’ Equity (Unaudited) - USD ($)	Common Stock	Additional Paid-in capital	Accumulated Deficit	Total
Balance at Jun. 30, 2022	$ 1,066	$ 8,781,361	$ (3,682,484)	$ 5,099,943
Balance (in Shares) at Jun. 30, 2022	10,650,002
Issuance of common stock, net of offering costs	$ 51	1,426,564		1,426,615
Issuance of common stock, net of offering costs (in Shares)	517,000
Issuance of common stock for services	$ 15	299,985		300,000
Issuance of common stock for services (in Shares)	150,000
Stock-based compensation		177,451		177,451
Net loss			(2,610,590)	(2,610,590)
Balance at Dec. 31, 2022	$ 1,132	10,685,361	(6,293,074)	4,393,419
Balance (in Shares) at Dec. 31, 2022	11,317,002
Balance at Sep. 30, 2022	$ 1,066	8,851,451	(5,212,525)	3,639,992
Balance (in Shares) at Sep. 30, 2022	10,650,002
Issuance of common stock, net of offering costs	$ 51	1,426,564		1,426,615
Issuance of common stock, net of offering costs (in Shares)	517,000
Issuance of common stock for services	$ 15	299,985		300,000
Issuance of common stock for services (in Shares)	150,000
Stock-based compensation		107,361		107,361
Net loss			(1,080,549)	(1,080,549)
Balance at Dec. 31, 2022	$ 1,132	10,685,361	(6,293,074)	4,393,419
Balance (in Shares) at Dec. 31, 2022	11,317,002
Balance at Jun. 30, 2023	$ 1,282	15,171,074	(9,062,066)	6,110,290
Balance (in Shares) at Jun. 30, 2023	12,817,500
Repurchase of common stock	$ (65)	(3,936)		(4,001)
Repurchase of common stock (in Shares)	(649,570)
Stock-based compensation		376,496		376,496
Net loss			(2,610,829)	(2,610,829)
Balance at Dec. 31, 2023	$ 1,217	15,543,634	(11,672,895)	3,871,956
Balance (in Shares) at Dec. 31, 2023	12,167,930
Balance at Sep. 30, 2023	$ 1,217	15,407,715	(10,544,375)	4,864,557
Balance (in Shares) at Sep. 30, 2023	12,167,930
Stock-based compensation		135,919		135,919
Net loss			(1,128,520)	(1,128,520)
Balance at Dec. 31, 2023	$ 1,217	$ 15,543,634	$ (11,672,895)	$ 3,871,956
Balance (in Shares) at Dec. 31, 2023	12,167,930

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders’ Equity (Unaudited) (Parentheticals) - USD ($)	3 Months Ended	6 Months Ended
	Dec. 31, 2022	Dec. 31, 2022
Statement of Stockholders' Equity [Abstract]
Net offering costs	$ 124,385	$ 124,385

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net loss	$ (2,610,829)	$ (2,610,590)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred compensation	18,938	491,954
Stock-based compensation expense	376,496	177,451
Depreciation and amortization expense	131,783	93,347
Change in accounts receivable	(3,753)
Change in prepaids and other current assets	(135,704)	(191,638)
Change in accounts payable	(298,974)	57,283
Change in accrued expenses and other current liabilities	41,698	(19,002)
Net cash used in operating activities	(2,480,345)	(2,001,195)
Investing activities:
Purchase of equipment	(164,290)	(26,629)
Payment for leasehold improvements		(77,197)
Net cash used in investing activities	(164,290)	(103,826)
Financing activities:
Repurchase of common stock	(4,001)
Proceeds from Private Placement, net of $124,385 offering costs		1,426,615
Net cash (used in) provided by financing activities	(4,001)	1,426,615
Net change in cash	(2,648,636)	(678,406)
Cash, beginning of period	5,071,690	3,740,722
Cash, end of period	$ 2,423,054	$ 3,062,316

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	6 Months Ended
	Dec. 31, 2022 USD ($)
Statement of Cash Flows [Abstract]
Proceeds from private placement, net of offering costs	$ 124,385

The Company

The Company	6 Months Ended
	Dec. 31, 2023
The Company [Abstract]
The Company	Note 1 – The Company Aeluma, Inc., headquartered in Goleta, California, is engaged in the research and development of infrared (IR) optical sensors to disrupt the market for IR sensors, and using its proprietary technology aims to produce a much higher performance alternative to today’s low-cost sensors at much lower prices than would otherwise be possible. The focus of Aeluma, Inc. (“the Company”) will be the image sensor market. Initial efforts hope to penetrate the 3D imaging and sensing (mobile and consumer, defense and aerospace, industrial, medical, auto) and LiDAR (robotic vehicles, advanced driver assistance systems vehicles (ADAS), topography, wind, industrial) markets. On June 22, 2021, Biond Photonics, Inc., a privately held California corporation (“Biond Photonics”) merged with and into our wholly owned subsidiary, Aeluma Operating Co., a corporation formed in the State of Delaware on June 22, 2021 (“Acquisition Sub”). Pursuant to this transaction (the “Merger”), Acquisition Sub was the surviving corporation and remained our wholly owned subsidiary, and all the outstanding stock of Biond Photonics was converted into shares of our common stock. As a result of the Merger, the Company acquired the business of Biond Photonics and continued the existing business operations of Biond Photonics as a public reporting company under the name Aeluma, Inc. Going Concern The Company incurred a net loss of $2,610,829 and $2,610,590 for the six months ended December 31, 2023 and 2022, respectively, and has accumulated deficit of $11,672,895 at December 31, 2023. In addition, the Company is in the research and development stage and has generated limited revenue to date. In order to support its operations, the Company will require additional infusions of cash from the sale of equity instruments or the issuance of debt instruments, or the commencement of profitable revenue generating activities. If adequate funds are not available or are not available on acceptable terms, the Company’s ability to fund its operations, develop or enhance its sensors in the future or respond to competitive pressures would be significantly limited. Such limitations could require the Company to curtail, suspend or discontinue parts of its business plan. These conditions raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”), which contemplate continuation of the Company as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that could result from the outcome of this uncertainty. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements have been presented in accordance with GAAP. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who is responsible for the Company’s integrity and objectivity. This Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended June 30, 2023. The accompanying consolidated financial statements and footnotes have been condensed and therefore do not contain all disclosures required by GAAP. The interim financial data are unaudited; however, in the opinion of Aeluma, Inc., the interim data include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Results for interim periods are not necessarily indicative of those to be expected for the full year. Use of Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Cash and Cash Equivalents The Company considers cash in banks, deposits in transit, and highly liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents. Concentration of Risk The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company’s accounts are insured by the FDIC but at times may exceed federally insured limits. Fair Value of Financial Instruments As defined in Financial Accounting Standards Board (“FASB”) ASC Topic No. 820, “Fair Value Measurements and Disclosures” (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer the liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses the market or income approach. Based on this approach, the Company utilizes certain assumptions about the risk inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the observability of the inputs used in the valuation techniques, the Company is required to provide the following information according to the fair value hierarchy. The fair value hierarchy ranks the quality and the reliability of the information used to determine fair values. As a basis for considering these assumptions, ASC 820 defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value. Level 1 – Unadjusted quoted prices in active, accessible market for identical assets or liabilities Level 2 – Other inputs that are directly or indirectly observable in the marketplace Level 3 – Unobservable inputs which are supported by little or no market activity The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, accounts receivable, accounts payable, accrued expenses and other current liabilities approximate their fair value due to the relatively short maturity of these items. Property and Equipment Property, equipment and leasehold improvements are reported at historical cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the less of the remaining lease term or the estimated useful lie of the improvements. Repairs and maintenance to these assets are charged to expense as incurred; major improvements enhancing the function and/or the asset’s useful life are capitalized. When items are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gains or losses arising from such transactions are recognized. Intangible Assets Intangible assets are associated with the Aeluma.com domain name and are amortized on a straight-line basis over 10 years. Revenue Recognition The Company follows a five-step approach for recognizing revenue, consisting of the following: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when, or as, the entity satisfies a performance obligation. Sales and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense. The Company does not have any significant financing components associated with its revenue contracts, as payment is received within one year. ● Product sales: Revenue is currently generated from multiple customers for small-volume orders ● Government contracts: Revenue is principally generated under research and development contracts with agencies of the U.S. government or with prime contractors. These contracts may include cost reimbursement and fixed firm price terms. The Company was awarded two government contracts of $237,071 and $239,998 for providing services and delivering materials during the second quarter of 2024. The awards are firm fixed contracts that shall be paid upon completion of performance and recognized as revenue for next 12 months. For the three months ended December 31, 2023, the Company recognized its revenue of $262,992 from government contracts. For the six months ended December 31, 2023, the company recognized its revenue of $295,392, of which $32,400 was from product sales for sampling purchases and $262,992 was from government contracts. As of December 31, 2023, the aggregate amount to remaining performance obligations for the government contracts was $435,463, which is expected to be recognized as revenue within next 12 months. Loss Per Share Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares outstanding plus potential dilutive common shares outstanding during the period. Potential dilutive securities, comprised of stock warrants and stock options, are not reflected in diluted loss per share because such shares are anti–dilutive. Dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Stock-Based Compensation The Company accounts for stock-based compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company’s estimate of expected volatility was based on the volatility of peers. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options. The Company accounts for forfeitures upon occurrence. Income Taxes The Company is expected to have net operating loss carryforwards that it can use to offset a certain amount of taxable income in the future. The Company is currently analyzing the amount of loss carryforwards that will be available to reduce future taxable income. The resulting deferred tax assets will be offset by a valuation allowance due to the uncertainty of its realization. The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before income taxes relates to the recognition of a valuation allowance for deferred income tax assets. The Company has adopted FASB ASC 740-10, “ Income Taxes” The Company will file tax returns in the U.S. federal jurisdiction and the state of California. The Company’s federal and state return forms are subject to review by the taxing authorities. The Company is not currently under examination by any taxing authority, nor has it been notified of an impending examination. Recent Accounting Pronouncements The Company has evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to the Company.

Stockholders_ Equity

Stockholders’ Equity	6 Months Ended
	Dec. 31, 2023
Stockholders’ Equity [Abstract]
Stockholders’ Equity	Note 3 – Stockholders’ Equity Authorized Shares The Company’s Articles of Incorporation authorize the issuance of two classes of shares of stock. The total number of shares which this corporation is authorized to issue is 50,000,000 shares of $0.0001 par value common stock and 10,000,000 of $0.0001 par value preferred stock. No On December 12, 2022, the Company sold an aggregate of 517,000 shares of common stock in a private placement offering (the “Offering”) at a price of $3.00 per share, with gross proceeds of $1,551,000 (before deducting placement agent fees and expenses of $124,385). On January 10, 2023, the Company held a second closing for an additional 214,667 shares of common stock, with gross proceeds of $644,000 (before deducting placement agent fees and expenses of $28,640). On March 31, 2023, the Company held a third closing for an additional 715,665 shares of common stock, with gross proceeds of $2,147,000 (before deducting placement agent fees and expenses of $117,830). On May 10, 2023, the Company held a fourth and final close for additional 570,166 shares of its common, with gross proceeds of $1,710,500 (before deducting placement agent fees and expenses of $140,160). Accordingly, the Company sold a total of 2,017,498 shares of common stock with a total gross proceeds of $6,052,500 (before deducting total placement agent fees and expenses of $411,015) in this private placement. The Offering was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated by the SEC thereunder. The common stock in the Offering was sold to “accredited investors,” as defined in Regulation D, and was conducted on a “reasonable best efforts” basis. Issued and Vested Shares to Officers On October 27, 2020, the Company issued 1,623,920 shares of common stock to Jonathan Klamkin, Director and Chief Executive Officer, and 1,623,920 shares of common stock to Lee McCarthy, Director, interim Chief Financial Officer and Chief Operations Officer, for an aggregate sum of $10,000 each. Initially 20% or 324,784 shares vested on October 27, 2020, and the remaining 1,299,136 shares vest in equal amounts, monthly over the subsequent 4 years. The stock purchase agreement contains a repurchase option whereby unvested shares may be repurchased by the Company, at the Company’s option. At December 31, 2023, Jonathan Klamkin had 1,353,267 vested shares and 270,653 unvested shares, and Lee McCarthy had 974,350 vested shares. On November 17, 2022, Lee McCarthy left the Company and, on September 10, 2023, the Company exercised its option to purchase 649,570 unvested restricted shares Lee McCarthy held for a total consideration of $4,001, the initial purchase price of these shares. Registration Rights Agreement The Company entered into a registration rights agreement that provides for certain liquidated damages upon the occurrence of a “Registration Event,” which is defined as the occurrence of any of the following events: (a) the Company fails to file with the Commission the Registration Statement on or before the Registration Filing Date; (b) the Registration Statement is not declared effective by the Commission on or before the Registration Effectiveness Date; (c) after the SEC Effective Date, the Registration Statement ceases for any reason to remain effective or the Holders of Registrable Securities covered thereby are otherwise not permitted to utilize the prospectus therein to resell the Registrable Securities covered thereby, except for Blackout Periods permitted herein; or (d) following the listing or inclusion for quotation on an Approved Market, the Registrable Securities, if issued and outstanding, are not listed or included for quotation on an Approved Market, or trading of the Common Stock is suspended or halted on the Approved Market, which at the time constitutes the principal markets for the Common Stock, for more than three (3) full, consecutive Trading Days (other than as a result of (A) actions or inactions of parties other than the Company or its affiliates or of the Approved Market not reasonably in the control of the Company, or (B) suspension or halt of substantially all trading in equity securities (including the Common Stock) on the Approved Market). The maximum amount of liquidated damages that may be paid by the Company shall be an amount equal to eight percent (8%) of the shares covered by the registration rights agreement. This filing covered 11,010,002 shares. The Company currently expects to satisfy all of its obligations under the Registration Agreement and does not expect to pay any damages pursuant to this agreement; therefore, no liability has been recorded.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Dec. 31, 2023
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 4 – Stock-Based Compensation Restricted Stock Awards In June 2021, the Company sold 723,008 shares of common stock to certain individuals in exchange for future management advisory services, for discounted prices price ranging from $.0104 to $.0195 per share. The shares are subject to restrictions that allow for repurchase of the shares by the Company due to a termination of the service agreement or other certain provisions. This repurchase right declines on a pro-rata basis over vesting periods (corresponding to the service period) ranging from 2-4 years. Related to these issuances, the Company has recorded deferred compensation of $1,372,435 for the value of the shares in excess of the purchase price paid by the advisors. The deferred compensation was expensed as consulting expense in the consolidated statements of operation over the service period. In March 2022, the Company signed an agreement to issue 150,000 shares of common stock valued at $300,000 to a consultant for providing consulting services to the Company for eighteen months. Related to these issuances, the Company has recorded deferred compensation of $300,000 which was expensed as consulting expense in the consolidated statements of operation over the eighteen months. For the three months ended December 31, 2023 and 2022, $6,981 and $216,977, respectively, have been amortized in the consolidated statements of operations, and, for the six months ended December 31, 2023 and 2022, $18,938 and $491,954, respectively, have been amortized in the consolidated statements of operations. At December 31, 2023, $34,096 of deferred compensation included in the balance sheets is expected to be expensed in next two years. The following is a schedule summarizing restricted stock awards for the periods indicated: December 31, 2023 Three Months Ended Six Months Ended Number of Weighted Number of Weighted Beginning balance 21,619 $ 1.90 75,293 $ 1.97 Issued - - - - Vested (3,675 ) 1.90 (57,349 ) 1.99 Forfeited - - - - Ending balance 17,944 $ 1.90 17,944 $ 1.90 December 31, 2022 Three Months Ended Six Months Ended Number of Weighted Number of Weighted Beginning balance 257,724 $ 1.90 344,426 $ 1.90 Issued 150,000 2.00 150,000 2.00 Vested (111,702 ) 1.90 (198,404 ) 1.90 Forfeited - - - - Ending balance 296,022 $ 1.95 296,022 $ 1.95 Stock Options During the three months ended December 31, 2022, the Company issued 161,000 options to purchase common stock to employees. The options have an exercise price of $2.00 or $2. During the three months ended June 30, 2023, the Company issued 163,000 options to purchase common stock to a consultant and employees. The options expire in 10 years and have an exercise price of $2.60 with immediate vesting or $3.00 with a vesting schedule of 48 months. Stock options granted to employees are subject to the continued status as an employee to the Company through each vesting date. During the three months ended September 30, 2023, the Company issued 6,500 options to purchase common stock to consultants. The options expire in 10 years and have an exercise price that range from $2.90 to $3.90 with immediate vesting. During the three months ended December 31, 2023, the Company issued 7,000 options to purchase common stock to a consultant. The options expire in 10 years and have an exercise price that range from $2.50 to $3.43 with immediate vesting. The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions for to estimate the fair value of stock options for the period presented: Six Months Ended Weighted-average fair value $ 2.48 Expected volatility 104.9% – 106.6 % Expected term 5.0 years – 6.2 years Dividend yield 0.00 % Risk-free interest rate 3.94% – 4.92 % For the three months ended December 31, 2023 and 2022, stock-based compensation expenses for options granted were $135,919 and $107,361, respectively. For the six months ended December 31, 2023 and 2022, stock-based compensation expenses for options granted were $376,496 and $177,451, respectively. Unrecognized stock-based compensation expense was $942,146 and average expected recognition period was 1.5 years as of December 31, 2023. The following is a schedule summarizing stock option activities for the periods presented: Three Months Ended Number of Weighted Aggregate Outstanding at October 1, 2023 995,500 $ 2.33 $ 965,500 Granted 7,000 $ 2.90 Exercised - - Expired/forfeited (41,375 ) $ 2.09 Outstanding at December 31, 2023 961,125 $ 2.35 $ 566,485 Exercisable at December 31, 2023 481,560 $ 2.20 $ 350,521 Outstanding at October 1, 2022 697,750 $ 2.00 $ - Granted 161,000 2.08 Exercised - - Expired/forfeited - - Outstanding at December 31, 2022 858,750 $ 2.01 $ 846,250 Exercisable at December 31, 2022 193,875 $ 2.00 $ 193,875 (1) Represents the excess of the fair value on the last day of period (which was $2.90 and $3.00 as of December 31, 2023 and 2022, respectively) over the exercise price, multiplied by the number of options. Six Months Ended Number of Weighted Aggregate Outstanding at July 1, 2023 1,034,000 $ 2.31 $ 639,775 Granted 13,500 $ 3.11 Exercised - - Expired/forfeited (86,375 ) $ 2.04 Outstanding at December 31, 2023 961,125 $ 2.35 $ 566,485 Exercisable at December 31, 2023 481,560 $ 2.20 $ 350,521 Outstanding at July 1, 2022 817,500 $ 2.00 $ - Granted 161,000 2.08 Exercised - - Expired/forfeited (120,000 ) 2.00 Outstanding at December 31, 2022 858,750 $ 2.01 $ 846,250 Exercisable at December 31, 2022 193,875 $ 2.00 $ 193,875 (1) Represents the excess of the fair value on the last day of period (which was $2.90 and $3.00 as of December 31, 2023 and 2022, respectively) over the exercise price, multiplied by the number of options.

Facility Operating Lease

Facility Operating Lease	6 Months Ended
	Dec. 31, 2023
Facility Operating Lease [Abstract]
Facility Operating Lease	Note 5 – Facility Operating Lease On April 1, 2021, the Company commenced a 5-year operating lease for a facility in Santa Barbara, California with total lease payments of $781,813. The Company determined the lease constitutes a Right of Use (ROU) asset and has recorded the present value of the lease payments as an asset and liability per ASC 842. The lease agreement waived the first three months of rent with payments commencing July 1, 2021. At the commencement of the lease, the net present value of the lease payments was $767,553. In addition to these lease payments, the Company is also responsible for its shares of common area operating expenses and electricity. Such expenses are considered variable costs and are not included in the measurement of the lease liability. The lease agreement also provides for the option to extend the lease for two additional sixty-month periods. On July 1, 2023, one of the two options to extend was considered reasonably certain of exercise and the Company remeasured the ROU asset and lease liability. The Company recorded the net present value of $1,189,606 for both the ROU asset and lease liability on July 1, 2023. The following table presents maturities of operating lease liabilities on an undiscounted basis as of December 31, 2023: For the year ending June 30, Remainder of 2024 $ 83,058 2025 169,224 2026 173,454 2027 177,791 2028 182,235 Thereafter 524,526 Total 1,310,288 Less imputed interest (179,407 ) Total lease liability 1,130,881 Less: lease liability, current portion 124,145 Lease liability, long term portion $ 1,006,736 The lease term and the discount rate for the lease at December 31, 2023 is 7.3 years and 4.00%, respectively. The total lease payments were $49,344 and $32,359 for the three months ended December 31, 2023 and 2022, respectively, and $94,258 and $64,719 for the six months ended December 31, 2023 and 2022, respectively. The variable costs for common area operating expenses and electricity were $58,800, and $70,016 for the three months ended December 31, 2023 and 2022, respectively and $151,846 and $173,811 for the six months ended December 31, 2023 and 2022. In April 1, 2021, the Company subleased a portion of their facility. The sub-lease provided for base monthly rent of $13,013 through May 31, 2021 and $8,400 starting June 1, 2021 plus common area operating and utility costs. The sublease was amended again on May 17, 2022 to sublease a smaller portion of the property at a base rental rate of $5,200 per month effective June 1, 2022. The Company recognized sub-lease income of $74,165 and $110,516, including reimbursement of common area operating and utility costs, for the three and six months ended December 31, 2022. The sub-lease ended in March 2023.

Warrants to Purchase Common Sto

Warrants to Purchase Common Stock	6 Months Ended
	Dec. 31, 2023
Warrants to Purchase Common Stock [Abstract]
Warrants to Purchase Common Stock	Note 6 – Warrants to Purchase Common Stock In connection with the Offering held from December 2022 through May 2023, the Company issued warrants of 85,653 to purchase common stock to the Placement Agents. The warrants carry a term of 5 years and an exercise price of $3.00. The following warrants to purchase common stock were outstanding as of December 31, 2023: Number of Shares Exercise Price Expiration Date 308,250 $ 2.00 June 22, 2026 40,250 2.00 June 28, 2026 11,500 2.00 July 1, 2027 29,067 3.00 December 22, 2027 4,933 3.00 January 10, 2028 6,720 3.00 March 31, 2028 44,933 3.00 May 10, 2028 445,653

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been presented in accordance with GAAP. The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management, who is responsible for the Company’s integrity and objectivity. This Quarterly Report on Form 10-Q for the quarter ended December 31, 2023, should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended June 30, 2023. The accompanying consolidated financial statements and footnotes have been condensed and therefore do not contain all disclosures required by GAAP. The interim financial data are unaudited; however, in the opinion of Aeluma, Inc., the interim data include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods. Results for interim periods are not necessarily indicative of those to be expected for the full year.
Use of Estimates and Assumptions	Use of Estimates and Assumptions The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash in banks, deposits in transit, and highly liquid debt instruments purchased with original maturities of three months or less to be cash and cash equivalents.
Concentration of Risk	Concentration of Risk The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company’s accounts are insured by the FDIC but at times may exceed federally insured limits.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As defined in Financial Accounting Standards Board (“FASB”) ASC Topic No. 820, “Fair Value Measurements and Disclosures” (“ASC 820”), fair value is the price that would be received to sell an asset or paid to transfer the liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses the market or income approach. Based on this approach, the Company utilizes certain assumptions about the risk inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based on the observability of the inputs used in the valuation techniques, the Company is required to provide the following information according to the fair value hierarchy. The fair value hierarchy ranks the quality and the reliability of the information used to determine fair values. As a basis for considering these assumptions, ASC 820 defines a three-tier value hierarchy that prioritizes the inputs used in the valuation methodologies in measuring fair value. Level 1 – Unadjusted quoted prices in active, accessible market for identical assets or liabilities Level 2 – Other inputs that are directly or indirectly observable in the marketplace Level 3 – Unobservable inputs which are supported by little or no market activity The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying values of the Company’s cash, accounts receivable, accounts payable, accrued expenses and other current liabilities approximate their fair value due to the relatively short maturity of these items.
Property and Equipment	Property and Equipment Property, equipment and leasehold improvements are reported at historical cost, net of accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the less of the remaining lease term or the estimated useful lie of the improvements. Repairs and maintenance to these assets are charged to expense as incurred; major improvements enhancing the function and/or the asset’s useful life are capitalized. When items are sold or retired, the related cost and accumulated depreciation are removed from the accounts and any gains or losses arising from such transactions are recognized.
Intangible Assets	Intangible Assets Intangible assets are associated with the Aeluma.com domain name and are amortized on a straight-line basis over 10 years.
Revenue Recognition	Revenue Recognition The Company follows a five-step approach for recognizing revenue, consisting of the following: (1) identifying the contract with a customer; (2) identifying the performance obligations in the contract; (3) determining the transaction price; (4) allocating the transaction price to the performance obligations in the contract; and (5) recognizing revenue when, or as, the entity satisfies a performance obligation. Sales and other taxes the Company collects concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense. The Company does not have any significant financing components associated with its revenue contracts, as payment is received within one year. ● Product sales: Revenue is currently generated from multiple customers for small-volume orders ● Government contracts: Revenue is principally generated under research and development contracts with agencies of the U.S. government or with prime contractors. These contracts may include cost reimbursement and fixed firm price terms. The Company was awarded two government contracts of $237,071 and $239,998 for providing services and delivering materials during the second quarter of 2024. The awards are firm fixed contracts that shall be paid upon completion of performance and recognized as revenue for next 12 months. For the three months ended December 31, 2023, the Company recognized its revenue of $262,992 from government contracts. For the six months ended December 31, 2023, the company recognized its revenue of $295,392, of which $32,400 was from product sales for sampling purchases and $262,992 was from government contracts. As of December 31, 2023, the aggregate amount to remaining performance obligations for the government contracts was $435,463, which is expected to be recognized as revenue within next 12 months.
Loss Per Share	Loss Per Share Basic loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of common shares outstanding plus potential dilutive common shares outstanding during the period. Potential dilutive securities, comprised of stock warrants and stock options, are not reflected in diluted loss per share because such shares are anti–dilutive. Dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company’s estimate of expected volatility was based on the volatility of peers. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options. The Company accounts for forfeitures upon occurrence.
Income Taxes	Income Taxes The Company is expected to have net operating loss carryforwards that it can use to offset a certain amount of taxable income in the future. The Company is currently analyzing the amount of loss carryforwards that will be available to reduce future taxable income. The resulting deferred tax assets will be offset by a valuation allowance due to the uncertainty of its realization. The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before income taxes relates to the recognition of a valuation allowance for deferred income tax assets. The Company has adopted FASB ASC 740-10, “ Income Taxes” The Company will file tax returns in the U.S. federal jurisdiction and the state of California. The Company’s federal and state return forms are subject to review by the taxing authorities. The Company is not currently under examination by any taxing authority, nor has it been notified of an impending examination.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has evaluated all issued but not yet effective accounting pronouncements and determined that they are either immaterial or not relevant to the Company.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Dec. 31, 2023
Stock-Based Compensation [Abstract]
Schedule of Restricted Stock Awards	The following is a schedule summarizing restricted stock awards for the periods indicated: December 31, 2023 Three Months Ended Six Months Ended Number of Weighted Number of Weighted Beginning balance 21,619 $ 1.90 75,293 $ 1.97 Issued - - - - Vested (3,675 ) 1.90 (57,349 ) 1.99 Forfeited - - - - Ending balance 17,944 $ 1.90 17,944 $ 1.90 December 31, 2022 Three Months Ended Six Months Ended Number of Weighted Number of Weighted Beginning balance 257,724 $ 1.90 344,426 $ 1.90 Issued 150,000 2.00 150,000 2.00 Vested (111,702 ) 1.90 (198,404 ) 1.90 Forfeited - - - - Ending balance 296,022 $ 1.95 296,022 $ 1.95
Schedule of Estimates the Fair Value of Each Option Award	The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions for to estimate the fair value of stock options for the period presented: Six Months Ended Weighted-average fair value $ 2.48 Expected volatility 104.9% – 106.6 % Expected term 5.0 years – 6.2 years Dividend yield 0.00 % Risk-free interest rate 3.94% – 4.92 %
Schedule of Stock Option Activity	The following is a schedule summarizing stock option activities for the periods presented: Number of Weighted Aggregate Outstanding at October 1, 2023 995,500 $ 2.33 $ 965,500 Granted 7,000 $ 2.90 Exercised - - Expired/forfeited (41,375 ) $ 2.09 Outstanding at December 31, 2023 961,125 $ 2.35 $ 566,485 Exercisable at December 31, 2023 481,560 $ 2.20 $ 350,521 Outstanding at October 1, 2022 697,750 $ 2.00 $ - Granted 161,000 2.08 Exercised - - Expired/forfeited - - Outstanding at December 31, 2022 858,750 $ 2.01 $ 846,250 Exercisable at December 31, 2022 193,875 $ 2.00 $ 193,875 (1) Represents the excess of the fair value on the last day of period (which was $2.90 and $3.00 as of December 31, 2023 and 2022, respectively) over the exercise price, multiplied by the number of options. Number of Weighted Aggregate Outstanding at July 1, 2023 1,034,000 $ 2.31 $ 639,775 Granted 13,500 $ 3.11 Exercised - - Expired/forfeited (86,375 ) $ 2.04 Outstanding at December 31, 2023 961,125 $ 2.35 $ 566,485 Exercisable at December 31, 2023 481,560 $ 2.20 $ 350,521 Outstanding at July 1, 2022 817,500 $ 2.00 $ - Granted 161,000 2.08 Exercised - - Expired/forfeited (120,000 ) 2.00 Outstanding at December 31, 2022 858,750 $ 2.01 $ 846,250 Exercisable at December 31, 2022 193,875 $ 2.00 $ 193,875 (1) Represents the excess of the fair value on the last day of period (which was $2.90 and $3.00 as of December 31, 2023 and 2022, respectively) over the exercise price, multiplied by the number of options.

Facility Operating Lease (Table

Facility Operating Lease (Tables)	6 Months Ended
	Dec. 31, 2023
Facility Operating Lease [Abstract]
Schedule of Maturities of Operating Lease Liabilities	The following table presents maturities of operating lease liabilities on an undiscounted basis as of December 31, 2023: For the year ending June 30, Remainder of 2024 $ 83,058 2025 169,224 2026 173,454 2027 177,791 2028 182,235 Thereafter 524,526 Total 1,310,288 Less imputed interest (179,407 ) Total lease liability 1,130,881 Less: lease liability, current portion 124,145 Lease liability, long term portion $ 1,006,736

Warrants to Purchase Common S_2

Warrants to Purchase Common Stock (Tables)	6 Months Ended
	Dec. 31, 2023
Warrants to Purchase Common Stock [Abstract]
Schedule of Warrants to Purchase Common Stock	The following warrants to purchase common stock were outstanding as of December 31, 2023: Number of Shares Exercise Price Expiration Date 308,250 $ 2.00 June 22, 2026 40,250 2.00 June 28, 2026 11,500 2.00 July 1, 2027 29,067 3.00 December 22, 2027 4,933 3.00 January 10, 2028 6,720 3.00 March 31, 2028 44,933 3.00 May 10, 2028 445,653

The Company (Details)

The Company (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Jun. 30, 2023
The Company [Abstract]
Incurred net loss	$ (1,128,520)	$ (1,080,549)	$ (2,610,829)	$ (2,610,590)
Accumulated deficit	$ (11,672,895)		$ (11,672,895)		$ (9,062,066)

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Line Items]
Amortized on a straight-line basis	10 years		10 years
Government contract revenue	$ 262,992		$ 262,992
Revenue	262,992		295,392
Product revenue			32,400
Revenue from remaining performance obligations	$ 435,463		435,463
Interest and penalties			0
Services [Member]
Summary of Significant Accounting Policies [Line Items]
Government contracts			237,071
Materials [Member]
Summary of Significant Accounting Policies [Line Items]
Government contracts			$ 239,998

Stockholders_ Equity (Details)

Stockholders’ Equity (Details) - USD ($)						6 Months Ended
	May 10, 2023	Mar. 31, 2023	Jan. 10, 2023	Dec. 12, 2022	Oct. 27, 2020	Dec. 31, 2023	Dec. 31, 2022	Sep. 10, 2023	Jun. 30, 2023
Stockholders’ Equity [Line Items]
Common stock, shares authorized						50,000,000			50,000,000
Common stock, per share (in Dollars per share)						$ 0.0001			$ 0.0001
Preferred stock, shares authorized						10,000,000			10,000,000
Preferred stock, par value (in Dollars per share)						$ 0.0001			$ 0.0001
Preferred shares issued
Additional shares issued						2,017,498
Gross proceeds (in Dollars)							$ 124,385
Fees and expenses (in Dollars)	$ 140,160	$ 117,830	$ 28,640	$ 124,385		$ 411,015
Aggregate amount (in Dollars)					$ 10,000
Shares Percentage					20%
Vested shares					324,784
Agreement percentage						8%
Covered shares						11,010,002
Private Placement [Member]
Stockholders’ Equity [Line Items]
Additional shares issued				517,000
Share price (in Dollars per share)				$ 3
Gross proceeds (in Dollars)				$ 1,551,000
Common Stock [Member]
Stockholders’ Equity [Line Items]
Additional shares issued	570,166	715,665	214,667
Gross proceeds (in Dollars)	$ 1,710,500	$ 2,147,000	$ 644,000			$ 6,052,500
Vest [Member]
Stockholders’ Equity [Line Items]
Vested shares					1,299,136
Vested shares monthly amount					4 years
Jonathan Klamkin [Member]
Stockholders’ Equity [Line Items]
Shares of common stock					1,623,920
Vested shares						1,353,267
Unvested shares						270,653
Lee McCarthy [Member]
Stockholders’ Equity [Line Items]
Share price (in Dollars per share)								$ 4,001
Shares of common stock					1,623,920
Vested shares						974,350
Unvested shares								649,570

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	1 Months Ended			3 Months Ended				6 Months Ended
	Dec. 31, 2022	Mar. 31, 2022	Jun. 30, 2021	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Stock-Based Compensation [Line Items]
Sale of common stock (in Shares)								2,017,498
Deferred compensation (in Dollars)		$ 300,000						$ 1,372,435
Common stock value (in Dollars)							$ 300,000		$ 300,000
Amortized cost (in Dollars)				$ 6,981			$ 216,977	18,938	$ 491,954
Deferred compensation (in Dollars)				$ 34,096				$ 34,096
Issued shares (in Shares)	177,451			376,496			177,451	376,496	177,451
Stock-based compensation expenses (in Dollars)				$ 135,919			$ 107,361
Unrecognized stock-based compensation (in Dollars)				$ 942,146				$ 942,146
Average expected recognition period								1 year 6 months
Excess of fair value price per share				$ 2.9			$ 3	$ 2.9	$ 3
Minimum [Member]
Stock-Based Compensation [Line Items]
Excess of fair value price per share			$ 0.0104
Vesting terms								2 years
Exercise price decrease per share					$ 2.9
Maximum [Member]
Stock-Based Compensation [Line Items]
Excess of fair value price per share			$ 0.0195
Vesting terms								4 years
Exercise price increase per share					$ 3.9
Consultant [Member]
Stock-Based Compensation [Line Items]
Issue of share (in Shares)		150,000
Common stock value (in Dollars)		$ 300,000
Issued shares (in Shares)				7,000	6,500			7,000
Exercise price decrease per share				$ 2.5
Exercise price increase per share				$ 3.43
Expiring period					10 years
Employees [Member]
Stock-Based Compensation [Line Items]
Issued shares (in Shares)	161,000					163,000	161,000		161,000
Exercise price decrease per share	$ 2					$ 2.6
Exercise price increase per share	$ 2.10					$ 3
Expiring period	10 years					10 years
Restricted Stock Awards [Member]
Stock-Based Compensation [Line Items]
Sale of common stock (in Shares)			723,008

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Restricted Stock Awards - Restricted Stock [Member] - $ / shares	3 Months Ended		6 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Schedule of Restricted Stock Awards [Line Items]
Number of Shares, Beginning balance	21,619	257,724	75,293	344,426
Weighted Average Grant Date Fair Value per Price, Outstanding beginning balance	$ 1.9	$ 1.9	$ 1.97	$ 1.9
Number of Shares, Issued		150,000		150,000
Weighted Average Grant Date Fair Value per Price, Issued		$ 2		$ 2
Number of Shares, Vested	(3,675)	(111,702)	(57,349)	(198,404)
Weighted Average Grant Date Fair Value per Price, Vested	$ 1.9	$ 1.9	$ 1.99	$ 1.9
Number of Shares, Forfeited
Weighted Average Grant Date Fair Value per Price, Forfeited
Number of Shares, Ending balance	17,944	296,022	17,944	296,022
Weighted Average Grant Date Fair Value per Price, Outstanding ending balance	$ 1.9	$ 1.95	$ 1.9	$ 1.95

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of Estimates the Fair Value of Each Option Award	6 Months Ended
	Dec. 31, 2023 $ / shares
Stock-Based Compensation [Line Items]
Weighted-average fair value (in Dollars per share)	$ 2.48
Dividend yield	0%
Minimum [Member]
Stock-Based Compensation [Line Items]
Expected volatility	104.90%
Expected term	5 years
Risk-free interest rate	3.94%
Maximum [Member]
Stock-Based Compensation [Line Items]
Expected volatility	106.60%
Expected term	6 years 2 months 12 days
Risk-free interest rate	4.92%

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of Stock Option Activity - USD ($)		3 Months Ended		6 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Schedule of Stock Option Activity [Abstract]
Number of Shares, Beginning balance		995,500	697,750	1,034,000	817,500
Weighted Average Grant Date Fair Value per Price, Outstanding beginning balance		$ 2.33	$ 2	$ 2.31	$ 2
Aggregate Intrinsic Value, Outstanding at Beginning	[1]	$ 965,500		$ 639,775
Number of Options, Granted		7,000	161,000	13,500	161,000
Weighted Average Exercise Price, Granted		$ 2.9	$ 2.08	$ 3.11	$ 2.08
Number of Options, Exercised
Weighted Average Exercise Price, Exercised
Number of Options, Expired/forfeited		(41,375)		(86,375)	(120,000)
Weighted Average Exercise Price, Expired/forfeited		$ 2.09		$ 2.04	$ 2
Number of Shares, Ending balance		961,125	858,750	961,125	858,750
Weighted Average Grant Date Fair Value per Price, Outstanding ending balance		$ 2.35	$ 2.01	$ 2.35	$ 2.01
Aggregate Intrinsic Value, Outstanding at Ending	[1]	$ 566,485	$ 846,250	$ 566,485	$ 846,250
Number of Options, Exercisable		481,560	193,875	481,560	193,875
Weighted Average Exercise Price, Exercisable		$ 2.2	$ 2	$ 2.2	$ 2
Aggregate Intrinsic Value, Exercisable	[1]	$ 350,521	$ 193,875	$ 350,521	$ 193,875
[1] Represents the excess of the fair value on the last day of period (which was $2.90 and $3.00 as of December 31, 2023 and 2022, respectively) over the exercise price, multiplied by the number of options.

Facility Operating Lease (Detai

Facility Operating Lease (Details) - USD ($)						3 Months Ended		6 Months Ended
	Jul. 01, 2023	Apr. 01, 2023	May 17, 2022	Jun. 01, 2021	May 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Facility Operating Lease [Line Items]
Operating lease payments		$ 781,813				$ 49,344	$ 32,359	$ 94,258	$ 64,719
Lease payments		$ 767,553
Net present value	$ 1,189,606
Operating lease term						7 years 3 months 18 days		7 years 3 months 18 days
Operating lease discount rate						4%		4%
Variable costs						$ 58,800	70,016	$ 151,846	173,811
Sub-lease income			$ 5,200	$ 8,400	$ 13,013		$ 74,165		$ 110,516

Facility Operating Lease (Det_2

Facility Operating Lease (Details) - Schedule of Maturities of Operating Lease Liabilities - USD ($)	Dec. 31, 2023	Jun. 30, 2023
Schedule of Maturities of Operating Lease Liabilities [Abstract]
Remainder of 2024	$ 83,058
2025	169,224
2026	173,454
2027	177,791
2028	182,235
Thereafter	524,526
Total	1,310,288
Less imputed interest	(179,407)
Total lease liability	1,130,881
Less: lease liability, current portion	124,145	$ 162,210
Lease liability, long term portion	$ 1,006,736	$ 296,452

Warrants to Purchase Common S_3

Warrants to Purchase Common Stock (Details) - $ / shares	Dec. 31, 2023	May 31, 2023
Warrants to Purchase Common Stock [Line Items]
Issued warrants		85,653
Warrant [Member]
Warrants to Purchase Common Stock [Line Items]
Warrant term	5 years
Exercise price	$ 3

Warrants to Purchase Common S_4

Warrants to Purchase Common Stock (Details) - Schedule of Warrants to Purchase Common Stock	Dec. 31, 2023 $ / shares shares
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	445,653
Exercise Price 2.00 One [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	308,250
Exercise Price (in Dollars per share) | $ / shares	$ 2
Expiration Date	Jun. 22, 2026
Exercise Price 2.00 Two [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	40,250
Exercise Price (in Dollars per share) | $ / shares	$ 2
Expiration Date	Jun. 28, 2026
Exercise Price 2.00 Three [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	11,500
Exercise Price (in Dollars per share) | $ / shares	$ 2
Expiration Date	Jul. 01, 2027
Exercise Price 3.00 One [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	29,067
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	Dec. 22, 2027
Exercise Price 3.00 Two [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	4,933
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	Jan. 10, 2028
Exercise Price 3.00 Three [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	6,720
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	Mar. 31, 2028
Exercise Price 3.00 Four [Member]
Schedule of Warrants to Purchase Common Stock [Line Items]
Number of Shares	44,933
Exercise Price (in Dollars per share) | $ / shares	$ 3
Expiration Date	May 10, 2028